1. Home
  2. SII vs PGEN Comparison

SII vs PGEN Comparison

Compare SII & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprott Inc.

SII

Sprott Inc.

N/A

Current Price

$107.46

Market Cap

2.7B

Sector

Finance

ML Signal

N/A

Logo Precigen Inc.

PGEN

Precigen Inc.

N/A

Current Price

$4.58

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SII
PGEN
Founded
2008
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.8B
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
SII
PGEN
Price
$107.46
$4.58
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
★ $132.07
$14.00
AVG Volume (30 Days)
101.1K
★ 7.3M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
★ 1.58%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.12
Revenue
N/A
★ $230,981,000.00
Revenue This Year
$42.44
$2,335.22
Revenue Next Year
N/A
$85.34
P/E Ratio
$63.42
★ $38.67
Revenue Growth
N/A
N/A
52 Week Low
$80.53
$3.04
52 Week High
$169.63
$8.98

Technical Indicators

Market Signals
Indicator
SII
PGEN
Relative Strength Index (RSI) 42.49 35.21
Support Level $101.76 $3.65
Resistance Level $109.99 $5.75
Average True Range (ATR) 4.00 0.47
MACD 0.70 -0.07
Stochastic Oscillator 41.61 21.58

Price Performance

Historical Comparison
SII
PGEN

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: